Abound Wealth Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Abound Wealth Management’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-192	Closed	-$10.4K	–	1441
2025 Q3	$10.4K	Buy	+192	New	+$11K	﹤0.01%	481
2025 Q2	–	Sell	-113	Closed	-$7.99K	–	1305
2025 Q1	$7.99K	Buy	+113	New	+$7.6K	﹤0.01%	445
2024 Q1	–	Sell	-347	Closed	-$33.5K	–	1302
2023 Q4	$33.5K	Sell	347 -159	-31%	-$14.1K	0.01%	185
2023 Q3	$44.8K	Buy	506 +496	+4,960%	+$44.1K	0.02%	145
2023 Q2	$867	Buy	+10	New	+$941	﹤0.01%	753

Other funds holding BMRN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Abound Wealth Management's BMRN Position: Q4 2025 in Review

Abound Wealth Management sold out of BioMarin Pharmaceuticals (BMRN) in Q4 2025, closing a stake of 192 shares — an estimated $10.4K sold.

Abound Wealth Management first reported a position in BMRN in Q2 2023 and held it in 5 quarters. The position peaked at $44.8K in Q3 2023. 540 funds tracked by Wall St. Rank hold BMRN as of Q4 2025.

Abound Wealth Management reported no remaining BioMarin Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
Abound Wealth Management sold 192 BioMarin Pharmaceuticals shares in Q4 2025, an estimated $10.4K.
Abound Wealth Management first reported a position in BioMarin Pharmaceuticals in Q2 2023 and held it in 5 quarters.
Abound Wealth Management's BioMarin Pharmaceuticals position peaked at $44.8K in Q3 2023.
540 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q4 2025.

Based on Abound Wealth Management's 13F filing for Q4 2025, filed 12 Jan 2026.